CY1105302T1 - Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης - Google Patents

Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης

Info

Publication number
CY1105302T1
CY1105302T1 CY20061100974T CY061100974T CY1105302T1 CY 1105302 T1 CY1105302 T1 CY 1105302T1 CY 20061100974 T CY20061100974 T CY 20061100974T CY 061100974 T CY061100974 T CY 061100974T CY 1105302 T1 CY1105302 T1 CY 1105302T1
Authority
CY
Cyprus
Prior art keywords
treatment
renal fibrosis
receptor antagonists
ccr1 receptor
peptide ccr1
Prior art date
Application number
CY20061100974T
Other languages
English (en)
Inventor
Richard Horuk
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of CY1105302T1 publication Critical patent/CY1105302T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αυτή κατευθύνεται σε φαρμακευτικές συνθέσεις χρήσιμες στη θεραπεία προϊούσης νεφρικής ίνωσης σε θηλαστικά που περιλαμβάνουν φαρμακευτικώς αποδεκτό έκδοχο και θεραπευτικώς αποτελεσματική ποσότητα ενός μη-πεπτιδίου ανταγωνιστού υποδοχέα CCR1.
CY20061100974T 2001-08-07 2006-07-13 Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης CY1105302T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31053801P 2001-08-07 2001-08-07
US10/205,713 US6812230B2 (en) 2001-08-07 2002-07-26 Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
PCT/US2002/024763 WO2003013656A2 (en) 2001-08-07 2002-08-05 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis

Publications (1)

Publication Number Publication Date
CY1105302T1 true CY1105302T1 (el) 2010-03-03

Family

ID=26900695

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100974T CY1105302T1 (el) 2001-08-07 2006-07-13 Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης

Country Status (10)

Country Link
US (1) US6812230B2 (el)
EP (1) EP1423166B1 (el)
JP (1) JP2005501084A (el)
AT (1) ATE323532T1 (el)
CY (1) CY1105302T1 (el)
DE (1) DE60210783T2 (el)
DK (1) DK1423166T3 (el)
ES (1) ES2261709T3 (el)
PT (1) PT1423166E (el)
WO (1) WO2003013656A2 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
EE200200567A (et) * 2000-03-31 2004-06-15 Pfizer Products Inc. Uued piperasiini derivaadid

Also Published As

Publication number Publication date
DE60210783T2 (de) 2007-04-12
DE60210783D1 (de) 2006-05-24
JP2005501084A (ja) 2005-01-13
PT1423166E (pt) 2006-08-31
EP1423166A2 (en) 2004-06-02
ES2261709T3 (es) 2006-11-16
EP1423166B1 (en) 2006-04-19
ATE323532T1 (de) 2006-05-15
US20030109534A1 (en) 2003-06-12
DK1423166T3 (da) 2006-08-21
US6812230B2 (en) 2004-11-02
WO2003013656A2 (en) 2003-02-20
WO2003013656A3 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
IS2991B (is) Lyfjafræðileg nanóagna samsetning takykínín viðtakamótlyfs
GEP20084571B (en) Triazole derivatives as vasopressin antagonists
NO20034689D0 (no) Farmasöytiske doseringsformer av amorf nelfinavir mesylat
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
CY1105302T1 (el) Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
CY1105321T1 (el) Μη πεπτιδικοι ανταγωνιστες υποδοχεα ccr1 σε συνδυασμο με κυκλοσπορινη α για τη θepαπεια της απορριψης καρδιακου μοσχευματος
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
LT2003015A (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection
DK1390063T3 (da) Farmaceutisk doseringsform af amorft nelfinavir-mesylat